ProKidney AI Stock Analysis
Want to see PROK full AI Analyst Report?
ProKidney (PROK) AI Stock Analysis
ProKidney
(NASDAQ:PROK)
The score is primarily pressured by very weak financial performance (minimal revenue, large losses, and substantial ongoing cash burn with multi-year negative equity), alongside bearish technicals (price below key moving averages and negative MACD). Corporate updates around rilparencel are a positive offset, but valuation support is limited given negative earnings and no dividend.
ProKidney (PROK) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $379.97M
- Dividend Yield
- ―
- Average Volume (3M)
- 1.41M
- Price to Earnings (P/E)
- -2.0
- Beta (1Y)
- 2.20
- Revenue Growth
- 55.22%
- EPS Growth
- 2.13%
- Country
- US
- Employees
- 231
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
ProKidney Business Overview & Revenue Model
Company Description
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived f...
ProKidney Financial Statement Overview
Summary
Financial performance is very weak: minimal and volatile revenue (~$0.8M TTM) against very large losses (~$86.7M TTM net loss) and heavy cash burn (TTM operating cash flow about -$141.2M; free cash flow about -$155.9M). Low debt (~$2.4M TTM) helps near-term leverage risk, but multi-year negative equity is a significant balance-sheet concern and implies continued financing needs.
Income Statement
12Very NegativeBalance Sheet
44NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 818.00K | 893.00K | 76.00K | 0 | 0 | 0 |
| Gross Profit | -2.07M | 893.00K | 76.00K | 0 | 0 | 0 |
| EBITDA | -159.91M | -144.62M | -158.49M | -125.59M | -143.99M | -53.12M |
| Net Income | -86.71M | -68.99M | -61.19M | -35.47M | -108.03M | -55.15M |
Balance Sheet | ||||||
| Total Assets | 249.02M | 335.57M | 441.07M | 420.55M | 518.00M | 40.30M |
| Cash, Cash Equivalents and Short-Term Investments | 181.56M | 270.02M | 358.29M | 362.95M | 490.25M | 20.56M |
| Total Debt | 3.52M | 4.04M | 3.24M | 4.41M | 2.40M | 1.33M |
| Total Liabilities | 26.18M | 34.78M | 39.44M | 29.22M | 13.06M | 13.38M |
| Stockholders Equity | -883.53M | -1.01B | -994.95M | -1.10B | -1.10B | 26.92M |
Cash Flow | ||||||
| Free Cash Flow | -159.73M | -135.31M | -155.86M | -124.27M | -78.94M | -55.49M |
| Operating Cash Flow | -141.17M | -120.12M | -126.35M | -90.07M | -77.09M | -50.30M |
| Investing Cash Flow | 104.74M | 103.97M | 20.41M | -329.98M | -1.74M | -5.19M |
| Financing Cash Flow | 26.35M | 25.57M | 144.41M | -9.55M | 548.52M | 71.47M |
ProKidney Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PROK, the sentiment is Negative. The current price of 1.13 is below the 20-day moving average (MA) of 1.32, below the 50-day MA of 1.58, and below the 200-day MA of 1.78, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 35.08 is Neutral, neither overbought nor oversold. The STOCH value of 37.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PROK.
ProKidney Risk Analysis
ProKidney disclosed 92 risk factors in its most recent earnings report. ProKidney reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksProKidney Peers Comparison
Overall Rating
GYRE56Neutral
DMAC51Neutral
ARDX49Neutral- PROK44Neutral
SANA44Neutral
AKBA42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| GYRE | 56Neutral | $487.81M | -15.27 | -22.44% | ― | 13.51% | -458.42% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| DMAC | 51Neutral | $521.46M | -13.42 | -77.68% | ― | ― | -3.42% |
| ARDX | 49Neutral | $756.63M | -13.94 | -35.30% | ― | 17.57% | 4.82% |
| PROK | 44Neutral | $335.63M | -1.98 | 8.83% | ― | 55.22% | 2.13% |
| SANA | 44Neutral | $728.11M | -4.32 | -97.08% | ― | ― | 45.15% |
| AKBA | 42Neutral | $150.44M | -3.58 | -169.15% | ― | -12.38% | -118.99% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PROK | Prokidney Corp. | 1.13 | -1.15 | -50.44% | |
| GYRE | Gyre Therapeutics Inc | 4.26 | -3.82 | -47.28% | |
| AKBA | Akebia Therapeutics | 0.57 | -1.19 | -67.44% | |
| ARDX | Ardelyx Inc | 3.13 | -2.70 | -46.31% | |
| DMAC | Diamedica Therapeutics | 9.66 | 4.24 | 78.23% | |
| SANA | Sana Biotechnology, Inc. | 2.29 | -1.37 | -37.43% |
ProKidney Corporate Events
ProKidney Updates Investor Presentation on Rilparencel Development
PositiveIn November 2026, ProKidney updated an investor presentation for use in interactions with investors and analysts. The presentation described rilparencel’s clinical development, including reported kidney-function stabilization in multiple Phase 2 stud...
ProKidney Announces At-the-Market Equity Offering Agreement
NeutralOn October 29, 2026, ProKidney Corp. entered into an Open Market Sale Agreement with Jefferies LLC, allowing the company to sell Class A common stock from time to time in an at-the-market offering on Nasdaq and other permitted venues. ProKidney filed...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026